We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Read MoreHide Full Article
Key Takeaways
MRK's phase III pipeline has nearly tripled since 2021, boosted by in-house growth and M&A deals.
MRK plans around 20 new drug and vaccine launches, many with blockbuster potential, over the next few years.
Capvaxive and Winrevair have shown strong launches, supporting growth as Keytruda's patent expiration nears.
Merck (MRK - Free Report) has built a substantial portfolio of new products and pipeline candidates in areas like oncology, vaccines, neuroscience, and infectious disease.
Merck’s phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals. The company is now positioned to launch around 20 new vaccines and drugs over the next few years, with many having blockbuster potential.
Merck has several promising candidates in late-stage development, such as enlicitide decanoate/MK-0616, an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis, bomedemstat/MK-3543 for essential thrombocythemia, myelofibrosis and polycythemia vera and Daiichi-Sankyo-partnered antibody-drug conjugates (ADCs).
Merck and Daiichi Sankyo are co-developing three DXd ADCs — patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan for several types of cancer indications.
To foray into the lucrative obesity market, Merck has in-licensed global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from China-based biotech Hansoh Pharma.
MRK's Keytruda Faces Patent Expiration in 2028
As Merck prepares for Keytruda’s eventual loss of exclusivity in 2028, the company’s expanding pipeline and new products are expected to play a key role in shaping its future business mix.
Besides working on various strategies to drive Keytruda's long-term growth, Merck is also pinning hopes on its new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension (PAH) drug, Winrevair, to boost its top line once Keytruda loses exclusivity. Both products have witnessed a strong launch so far.
Merck’s long-acting monoclonal antibody, Enflonsia (clesrovimab), for the prevention of respiratory syncytial virus was approved by the FDA earlier this month.
Keytruda, a PD-L1 inhibitor approved for several types of cancer, generated sales of $7.21 billion in the first quarter of 2025, up 6% year over year. Our model estimates for Keytruda suggest a CAGR of 5.4% over the next three years.
However, at present, it is not quite clear whether Merck’s new products and pipeline candidates can help the company successfully navigate the Keytruda LOE period and potential competition for the drug.
PD-L1 Inhibitors Competing With Keytruda
Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s (RHHBY - Free Report) Tecentriq and AstraZeneca’s (AZN - Free Report) Imfinzi.
BMY’s Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $2.26 billion in Opdivo sales during the first quarter of 2025, up 9% year over year.
Tecentriq is Roche’s leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 870 million in Tecentriq sales in the first quarter of 2025.
AZN’s Imfinzi generated sales of $1.26 billion in the first quarter of 2025, up 16%, driven by demand growth in lung and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca’s oncology portfolio.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have lost 19.9% compared with the industry’s decrease of 1.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 8.56 forward earnings, lower than 14.92 for the industry and its 5-year mean of 12.85.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has declined from $8.94 per share to $8.92, while the same for 2026 has decreased from $9.79 to $9.73 over the past 60 days.
Image: Bigstock
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
Key Takeaways
Merck (MRK - Free Report) has built a substantial portfolio of new products and pipeline candidates in areas like oncology, vaccines, neuroscience, and infectious disease.
Merck’s phase III pipeline has almost tripled since 2021, supported by in-house pipeline progress as well as the addition of candidates through M&A deals. The company is now positioned to launch around 20 new vaccines and drugs over the next few years, with many having blockbuster potential.
Merck has several promising candidates in late-stage development, such as enlicitide decanoate/MK-0616, an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart, a TL1A inhibitor for ulcerative colitis, bomedemstat/MK-3543 for essential thrombocythemia, myelofibrosis and polycythemia vera and Daiichi-Sankyo-partnered antibody-drug conjugates (ADCs).
Merck and Daiichi Sankyo are co-developing three DXd ADCs — patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan for several types of cancer indications.
To foray into the lucrative obesity market, Merck has in-licensed global rights to an investigational oral GLP-1 receptor agonist, HS-10535, from China-based biotech Hansoh Pharma.
MRK's Keytruda Faces Patent Expiration in 2028
As Merck prepares for Keytruda’s eventual loss of exclusivity in 2028, the company’s expanding pipeline and new products are expected to play a key role in shaping its future business mix.
Besides working on various strategies to drive Keytruda's long-term growth, Merck is also pinning hopes on its new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial hypertension (PAH) drug, Winrevair, to boost its top line once Keytruda loses exclusivity. Both products have witnessed a strong launch so far.
Merck’s long-acting monoclonal antibody, Enflonsia (clesrovimab), for the prevention of respiratory syncytial virus was approved by the FDA earlier this month.
Keytruda, a PD-L1 inhibitor approved for several types of cancer, generated sales of $7.21 billion in the first quarter of 2025, up 6% year over year. Our model estimates for Keytruda suggest a CAGR of 5.4% over the next three years.
However, at present, it is not quite clear whether Merck’s new products and pipeline candidates can help the company successfully navigate the Keytruda LOE period and potential competition for the drug.
PD-L1 Inhibitors Competing With Keytruda
Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s (RHHBY - Free Report) Tecentriq and AstraZeneca’s (AZN - Free Report) Imfinzi.
BMY’s Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $2.26 billion in Opdivo sales during the first quarter of 2025, up 9% year over year.
Tecentriq is Roche’s leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 870 million in Tecentriq sales in the first quarter of 2025.
AZN’s Imfinzi generated sales of $1.26 billion in the first quarter of 2025, up 16%, driven by demand growth in lung and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca’s oncology portfolio.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have lost 19.9% compared with the industry’s decrease of 1.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 8.56 forward earnings, lower than 14.92 for the industry and its 5-year mean of 12.85.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has declined from $8.94 per share to $8.92, while the same for 2026 has decreased from $9.79 to $9.73 over the past 60 days.
Image Source: Zacks Investment Research
Merck has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.